This report provides a comprehensive analysis of the global ophthalmic perfluorocarbon liquids market, projecting steady growth through 2032. Driven by an aging population and rising vitrectomy surgical volumes, the market is shifting toward high-purity perfluorooctane formulations for complex retinal detachment treatments. The study evaluates key segments by type, specification, and application, while examining regional dynamics, regulatory landscapes, and competitive strategies among leading manufacturers to identify emerging opportunities and long-term industry trajectories.

Market Overview

The global Ophthalmic Perfluorocarbon Liquids market is projected to grow from US$ 120 million in 2025 to US$ 184 million in 2032, representing a compound annual growth rate (CAGR) of 6.3% from 2026 to 2032.

In 2025, global production of Ophthalmic Perfluorocarbon Liquids reached approximately 760 k units, with an average global market price of around US$162 per unit.

Product Definition and Functionality

Ophthalmic perfluorocarbon liquids (PFCLs) are specialized liquids utilized in ophthalmic vitreoretinal surgery. Chemically, the hydrogen atoms on the carbon atoms within the molecules are replaced by fluorine atoms, resulting in high density and excellent chemical stability.

During surgical procedures, PFCLs serve to effectively separate fluid and blood located under the retina, assisting in the restoration of the normal retinal position, particularly when treating complex retinal detachment conditions. However, due to potential intraocular toxicity, PFCLs are currently utilized only as a temporary vitreous filler and must be removed immediately following surgery.

Market Dynamics

Growth Drivers

• Accelerating Population Aging: Global demand is anchored in demographic shifts. According to China's National Bureau of Statistics, the rising proportion of citizens aged 65 and above is driving a higher incidence of age-related retinal conditions, subsequently increasing vitrectomy surgical volumes. This trend provides a stable clinical demand base for PFCLs as temporary intraoperative tamponade agents.
• Supply Chain Advancements: Upstream fluorocarbon raw material production capacity is scaling up to strengthen supply chain autonomy.

Product Trends and Technological Evolution

• Formulation Shifts: While early formulations based on perfluorodecalin have established extensive global clinical experience, concerns regarding purity and postoperative residue have shifted industry focus toward high-purity perfluorooctane. Notably, the U.S. FDA approved purified perfluorooctane in 1996, leading to multiple subsequent products entering clinical use.
• Market Trajectories: The market is evolving along two principal paths: product-level technological upgrading and regional structural substitution.

Regulatory Landscape

• Classification: These products are classified as Class III high-risk medical devices across major global markets, necessitating rigorous premarket approval and lifecycle quality management.
• Regional Regulations:
• China: The NMPA issued specific registration review guidelines in 2019. Additionally, provincial-level volume-based procurement initiatives are introducing price linkage mechanisms with explicit price ceilings and requirements that bids do not exceed national historical lows. These procurement rules maintain clinical end-user discretion in volume allocation, meaning products lacking clinical endorsement may face share erosion even if they successfully win a bid.
• European Union: The EU REACH regulation imposes additional compliance obligations on fluorinated chemicals.

Market Segmentation

By Type

• Perfluorooctane
• Perfluorodecalin

By Specification

• 5 ml/unit
• 7 ml/unit

By Package

• Sterile Vials
• Pre-filled Syringes

By Application

• Hospital
• Ophthalmology Clinic

By Geography

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

This report analyzes the strategies of leading global companies, focusing on their Ophthalmic Perfluorocarbon Liquids portfolios and capabilities, market entry strategies, market positions, and geographic footprints. The following companies are profiled based on primary expert input and analysis of their coverage, product portfolio, and market penetration:

• Alcon
• Bausch + Lomb
• BVI Medical
• Geuder AG
• DORC (ZEISS)
• Alchimia srl
• Pharmpur
• Toomac Ophthalmic
• Micromed srl
• Biotech Healthcare Group
• Shanghai Jieshi Medical Technology

About the Report

Produced by LP Information, Inc. (LPI), the “Ophthalmic Perfluorocarbon Liquids Industry Forecast” reviews total global sales for 2025 and provides a comprehensive analysis of projected sales from 2026 through 2032.

This insight report delivers a detailed analysis in US$ millions, covering market sectors, regions, and sub-sectors. It highlights key trends related to product segmentation, company formation, revenue, market share, latest developments, and M&A activity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, the study offers a nuanced view of the current state and future trajectory of the global market.

Key Questions Addressed

• What is the 10-year outlook for the global Ophthalmic Perfluorocarbon Liquids market?
• What factors are driving Ophthalmic Perfluorocarbon Liquids market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Ophthalmic Perfluorocarbon Liquids market opportunities vary by end market size?
• How does Ophthalmic Perfluorocarbon Liquids break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Ophthalmic Perfluorocarbon Liquids Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Ophthalmic Perfluorocarbon Liquids by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Ophthalmic Perfluorocarbon Liquids by Country/Region, 2021, 2025 & 2032

  • 2.2 Ophthalmic Perfluorocarbon Liquids Segment by Type

    • 2.2.1 Perfluorooctane

    • 2.2.2 Perfluorodecalin

    • 2.2.3 Ophthalmic Perfluorocarbon Liquids Sales by Type

      • 2.2.3.1 Global Ophthalmic Perfluorocarbon Liquids Sales Market Share by Type (2021-2026)
      • 2.2.3.2 Global Ophthalmic Perfluorocarbon Liquids Revenue and Market Share by Type (2021-2026)
      • 2.2.3.3 Global Ophthalmic Perfluorocarbon Liquids Sale Price by Type (2021-2026)

  • 2.3 Ophthalmic Perfluorocarbon Liquids Segment by Specification

    • 2.3.1 5 ml/unit

    • 2.3.2 7 ml/unit

    • 2.3.3 Ophthalmic Perfluorocarbon Liquids Sales by Specification

      • 2.3.3.1 Global Ophthalmic Perfluorocarbon Liquids Sales Market Share by Specification (2021-2026)
      • 2.3.3.2 Global Ophthalmic Perfluorocarbon Liquids Revenue and Market Share by Specification (2021-2026)
      • 2.3.3.3 Global Ophthalmic Perfluorocarbon Liquids Sale Price by Specification (2021-2026)

  • 2.4 Ophthalmic Perfluorocarbon Liquids Segment by Package

    • 2.4.1 Sterile Vials

    • 2.4.2 Pre-filled Syringes

    • 2.4.3 Ophthalmic Perfluorocarbon Liquids Sales by Package

      • 2.4.3.1 Global Ophthalmic Perfluorocarbon Liquids Sales Market Share by Package (2021-2026)
      • 2.4.3.2 Global Ophthalmic Perfluorocarbon Liquids Revenue and Market Share by Package (2021-2026)
      • 2.4.3.3 Global Ophthalmic Perfluorocarbon Liquids Sale Price by Package (2021-2026)

  • 2.5 Ophthalmic Perfluorocarbon Liquids Segment by Application

    • 2.5.1 Hospital

    • 2.5.2 Ophthalmology Clinic

    • 2.5.3 Ophthalmic Perfluorocarbon Liquids Sales by Application

      • 2.5.3.1 Global Ophthalmic Perfluorocarbon Liquids Sale Market Share by Application (2021-2026)
      • 2.5.3.2 Global Ophthalmic Perfluorocarbon Liquids Revenue and Market Share by Application (2021-2026)
      • 2.5.3.3 Global Ophthalmic Perfluorocarbon Liquids Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Ophthalmic Perfluorocarbon Liquids Breakdown Data by Company

    • 3.1.1 Global Ophthalmic Perfluorocarbon Liquids Annual Sales by Company (2021-2026)

    • 3.1.2 Global Ophthalmic Perfluorocarbon Liquids Sales Market Share by Company (2021-2026)

  • 3.2 Global Ophthalmic Perfluorocarbon Liquids Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Ophthalmic Perfluorocarbon Liquids Revenue by Company (2021-2026)

    • 3.2.2 Global Ophthalmic Perfluorocarbon Liquids Revenue Market Share by Company (2021-2026)

  • 3.3 Global Ophthalmic Perfluorocarbon Liquids Sale Price by Company

  • 3.4 Key Manufacturers Ophthalmic Perfluorocarbon Liquids Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Ophthalmic Perfluorocarbon Liquids Product Location Distribution

    • 3.4.2 Players Ophthalmic Perfluorocarbon Liquids Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Ophthalmic Perfluorocarbon Liquids by Geographic Region

  • 4.1 World Historic Ophthalmic Perfluorocarbon Liquids Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Ophthalmic Perfluorocarbon Liquids Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Ophthalmic Perfluorocarbon Liquids Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Ophthalmic Perfluorocarbon Liquids Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Ophthalmic Perfluorocarbon Liquids Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Ophthalmic Perfluorocarbon Liquids Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Ophthalmic Perfluorocarbon Liquids Sales Growth

  • 4.4 APAC Ophthalmic Perfluorocarbon Liquids Sales Growth

  • 4.5 Europe Ophthalmic Perfluorocarbon Liquids Sales Growth

  • 4.6 Middle East & Africa Ophthalmic Perfluorocarbon Liquids Sales Growth

• 5 Americas

  • 5.1 Americas Ophthalmic Perfluorocarbon Liquids Sales by Country

    • 5.1.1 Americas Ophthalmic Perfluorocarbon Liquids Sales by Country (2021-2026)

    • 5.1.2 Americas Ophthalmic Perfluorocarbon Liquids Revenue by Country (2021-2026)

  • 5.2 Americas Ophthalmic Perfluorocarbon Liquids Sales by Type (2021-2026)

  • 5.3 Americas Ophthalmic Perfluorocarbon Liquids Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Ophthalmic Perfluorocarbon Liquids Sales by Region

    • 6.1.1 APAC Ophthalmic Perfluorocarbon Liquids Sales by Region (2021-2026)

    • 6.1.2 APAC Ophthalmic Perfluorocarbon Liquids Revenue by Region (2021-2026)

  • 6.2 APAC Ophthalmic Perfluorocarbon Liquids Sales by Type (2021-2026)

  • 6.3 APAC Ophthalmic Perfluorocarbon Liquids Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Ophthalmic Perfluorocarbon Liquids by Country

    • 7.1.1 Europe Ophthalmic Perfluorocarbon Liquids Sales by Country (2021-2026)

    • 7.1.2 Europe Ophthalmic Perfluorocarbon Liquids Revenue by Country (2021-2026)

  • 7.2 Europe Ophthalmic Perfluorocarbon Liquids Sales by Type (2021-2026)

  • 7.3 Europe Ophthalmic Perfluorocarbon Liquids Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Ophthalmic Perfluorocarbon Liquids by Country

    • 8.1.1 Middle East & Africa Ophthalmic Perfluorocarbon Liquids Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Ophthalmic Perfluorocarbon Liquids Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Ophthalmic Perfluorocarbon Liquids Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Ophthalmic Perfluorocarbon Liquids Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Ophthalmic Perfluorocarbon Liquids

  • 10.3 Manufacturing Process Analysis of Ophthalmic Perfluorocarbon Liquids

  • 10.4 Industry Chain Structure of Ophthalmic Perfluorocarbon Liquids

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Ophthalmic Perfluorocarbon Liquids Distributors

  • 11.3 Ophthalmic Perfluorocarbon Liquids Customer

• 12 World Forecast Review for Ophthalmic Perfluorocarbon Liquids by Geographic Region

  • 12.1 Global Ophthalmic Perfluorocarbon Liquids Market Size Forecast by Region

    • 12.1.1 Global Ophthalmic Perfluorocarbon Liquids Forecast by Region (2027-2032)

    • 12.1.2 Global Ophthalmic Perfluorocarbon Liquids Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Ophthalmic Perfluorocarbon Liquids Forecast by Type (2027-2032)

  • 12.7 Global Ophthalmic Perfluorocarbon Liquids Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Alcon

    • 13.1.1 Alcon Company Information

    • 13.1.2 Alcon Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.1.3 Alcon Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Alcon Main Business Overview

    • 13.1.5 Alcon Latest Developments

  • 13.2 Bausch + Lomb

    • 13.2.1 Bausch + Lomb Company Information

    • 13.2.2 Bausch + Lomb Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.2.3 Bausch + Lomb Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Bausch + Lomb Main Business Overview

    • 13.2.5 Bausch + Lomb Latest Developments

  • 13.3 BVI Medical

    • 13.3.1 BVI Medical Company Information

    • 13.3.2 BVI Medical Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.3.3 BVI Medical Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 BVI Medical Main Business Overview

    • 13.3.5 BVI Medical Latest Developments

  • 13.4 Geuder AG

    • 13.4.1 Geuder AG Company Information

    • 13.4.2 Geuder AG Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.4.3 Geuder AG Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Geuder AG Main Business Overview

    • 13.4.5 Geuder AG Latest Developments

  • 13.5 DORC (ZEISS)

    • 13.5.1 DORC (ZEISS) Company Information

    • 13.5.2 DORC (ZEISS) Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.5.3 DORC (ZEISS) Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 DORC (ZEISS) Main Business Overview

    • 13.5.5 DORC (ZEISS) Latest Developments

  • 13.6 Alchimia srl

    • 13.6.1 Alchimia srl Company Information

    • 13.6.2 Alchimia srl Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.6.3 Alchimia srl Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Alchimia srl Main Business Overview

    • 13.6.5 Alchimia srl Latest Developments

  • 13.7 Pharmpur

    • 13.7.1 Pharmpur Company Information

    • 13.7.2 Pharmpur Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.7.3 Pharmpur Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Pharmpur Main Business Overview

    • 13.7.5 Pharmpur Latest Developments

  • 13.8 Toomac Ophthalmic

    • 13.8.1 Toomac Ophthalmic Company Information

    • 13.8.2 Toomac Ophthalmic Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.8.3 Toomac Ophthalmic Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Toomac Ophthalmic Main Business Overview

    • 13.8.5 Toomac Ophthalmic Latest Developments

  • 13.9 Micromed srl

    • 13.9.1 Micromed srl Company Information

    • 13.9.2 Micromed srl Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.9.3 Micromed srl Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Micromed srl Main Business Overview

    • 13.9.5 Micromed srl Latest Developments

  • 13.10 Biotech Healthcare Group

    • 13.10.1 Biotech Healthcare Group Company Information

    • 13.10.2 Biotech Healthcare Group Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.10.3 Biotech Healthcare Group Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 Biotech Healthcare Group Main Business Overview

    • 13.10.5 Biotech Healthcare Group Latest Developments

  • 13.11 Shanghai Jieshi Medical Technology

    • 13.11.1 Shanghai Jieshi Medical Technology Company Information

    • 13.11.2 Shanghai Jieshi Medical Technology Ophthalmic Perfluorocarbon Liquids Product Portfolios and Specifications

    • 13.11.3 Shanghai Jieshi Medical Technology Ophthalmic Perfluorocarbon Liquids Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.11.4 Shanghai Jieshi Medical Technology Main Business Overview

    • 13.11.5 Shanghai Jieshi Medical Technology Latest Developments

• 14 Research Findings and Conclusion